Morepen Laboratories Limited , a prominent player in the pharmaceutical sector, has announced a strategic move into the medical devices industry with the incorporation of a new step-down subsidiary, Sigmacheck Health Private Limited. The Ministry of Corporate Affairs approved the incorporation on August 13, 2025, marking a significant expansion for the company.

Key Details of the New Subsidiary

Strategic Rationale

The formation of Sigmacheck Health Private Limited aims to cater to the growing demands in the medical devices sector. This move aligns with Morepen Laboratories' strategy to diversify its portfolio and tap into the expanding healthcare equipment market.

Financial Aspects

Morepen Medipath Limited, the direct parent company, has subscribed to all 10,000 equity shares for a total consideration of ₹1,00,000, paid in cash. This investment underscores Morepen Laboratories' commitment to establishing a strong foothold in the medical devices industry.

Market Implications

The entry into the medical devices industry could potentially enhance Morepen Laboratories' market position and diversify its revenue sources. As the healthcare sector continues to evolve, the demand for innovative medical devices is likely to grow.

Looking Ahead

As Sigmacheck Health Private Limited begins its operations, investors and industry observers will be keen to see how this new venture contributes to Morepen Laboratories' overall growth strategy and financial performance in the coming years.

Morepen Laboratories continues to demonstrate its commitment to growth and innovation in the healthcare sector with this strategic move into the medical devices industry.

Morepen Laboratories , a leading pharmaceutical company, has announced its unaudited financial results for Q1, revealing a mixed performance compared to the previous year.

Financial Performance

The company reported a consolidated net profit of Rs 1074.83 lakhs for Q1, compared to Rs 3616.79 lakhs in the same quarter last year, marking a significant decrease. On a standalone basis, the net profit stood at Rs 806.12 lakhs, down from Rs 3504.96 lakhs in the previous year's corresponding quarter.

Dividend Record Date

Morepen Laboratories has set August 30 as the record date for the distribution of the final dividend. This distribution is subject to shareholder approval at the upcoming 40th Annual General Meeting (AGM).

Leadership Changes and Appointments

The board has approved several key decisions:

1. Re-appointment of Sanjay Suri as Whole-Time Director for a three-year term from August 13 to August 12.
2. Appointment of M/s. PD and Associates as Secretarial Auditor for a five-year period.

Business Restructuring

The company has approved an extension of time for transferring its Medical Devices Business to its subsidiary, Morepen Medipath Limited. This strategic move is likely aimed at streamlining operations and focusing on core competencies.

Shareholding Changes

Morepen Laboratories' shareholding in Dr. Morepen Limited has decreased significantly from 80% to 19.94% following equity transactions. This change in ownership structure may have implications for the company's overall strategy and operations.

Annual General Meeting

The 40th AGM of Morepen Laboratories is scheduled for September 6 and will be conducted via video conferencing, adapting to the evolving norms of corporate governance and shareholder engagement.

Despite the challenges reflected in the Q1 results, Morepen Laboratories continues to make strategic decisions aimed at long-term growth and operational efficiency. The company's focus on restructuring, leadership stability, and shareholder value through dividend distribution demonstrates its commitment to navigating the complex pharmaceutical market landscape.